{"product_id":"voxel-swot-analysis","title":"Voxel SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVoxel’s SWOT snapshot highlights its core tech strengths, market gaps, and regulatory risks—essential context for investors and strategists seeking competitive edge. Purchase the full SWOT analysis to access a research-backed, editable Word report and Excel matrix with actionable recommendations, financial context, and strategic scenarios to support pitches, planning, and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Poland\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoxel S.A. operates one of Poland’s largest private diagnostic-imaging networks with ~120 centers and ~1.2 million scans in 2024, securing ~25–30% share in private MRI\/CT volume; the scale drives strong brand recognition among public and private patients nationwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Technological Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoxel invests ~€35M since 2020 in high-field MRI, 128-slice CT and PET-CT oncology suites, maintaining a modern fleet that lifted scan throughput 18% and cut repeat scans 6% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Teleradiology Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough subsidiary Rezonans, Voxel offers advanced teleradiology for remote image interpretation, streamlining radiologist workflow and cutting turnaround times—Rezonans reported a 28% YoY volume rise in 2024 with 54% of reads for external hospitals. This service scales without proportional facility capex, drove ~12% of Voxel’s 2024 revenue (≈PLN 48m), and supports margin expansion by outsourcing peak loads and night coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Public Sector Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa significant portion of voxel revenue in from multi-year contracts with poland national health fund giving predictable cash flow that supports capital investments and five-year planning.\u003e\n\u003cpwinning nfz tenders repeatedly shows voxel meets strict public-health compliance and quality metrics reducing regulatory risk strengthening payer relations.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~55% revenue from NFZ (2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts = stable cash flow\u003c\/li\u003e\n\u003cli\u003eConsistent tender wins = regulatory compliance\u003c\/li\u003e\n\u003cli\u003eSupports long-term investment planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pwinning\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration and Diversified Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVoxel vertically integrates imaging and related services: its Alteris subsidiary produced ~1,200 GBq of PET radiopharmaceuticals in 2024, covering ~70% of Voxel’s PET‑CT demand and cutting external vendor spend by an estimated €3.5m in 2024.\u003c\/p\u003e\n\u003cp\u003eVoxel also sells hospital IT solutions, contributing ~15% of 2024 revenue and boosting client retention through bundled contracts and recurring service fees.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAlteris: ~1,200 GBq radiotracer output (2024)\u003c\/li\u003e\n\u003cli\u003eSupply coverage: ~70% of PET demand\u003c\/li\u003e\n\u003cli\u003eVendor cost saved: ~€3.5m (2024)\u003c\/li\u003e\n\u003cli\u003eIT solutions: ~15% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eHigher retention via bundled contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoxel: Market-leading imaging chain — 120 centers, 1.2M scans, stable NFZ-backed growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVoxel is a market leader with ~120 centers and ~1.2M scans (2024), ~25–30% private MRI\/CT share; €35M capex since 2020 lifted throughput 18% and cut repeats 6%; Rezonans teleradiology drove 28% volume growth and ~12% revenue (~PLN48m); ~55% revenue from NFZ gives stable cash flow; Alteris produced ~1,200 GBq (70% PET coverage) saving ~€3.5m; IT solutions = ~15% revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCenters\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScans\u003c\/td\u003e\n\u003ctd\u003e~1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNFZ rev share\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRezonans rev\u003c\/td\u003e\n\u003ctd\u003e~12% (PLN48m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlteris output\u003c\/td\u003e\n\u003ctd\u003e~1,200 GBq (70% PET)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT rev\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Voxel’s business strategy, highlighting internal capabilities, market strengths, operational gaps, and external opportunities and threats that shape its competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a compact, visual SWOT layout to quickly align teams and prioritize strategic responses, reducing meeting time and decision friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Capital Expenditure Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe medical diagnostic sector demands continuous, large capex: in 2024 global imaging equipment spend was about $35.6B, and Voxel must sink a sizable share of cash flow into new scanners, AI software, and facility upgrades to avoid obsolescence.\u003c\/p\u003e\n\u003cp\u003eHigh capital intensity narrows financial flexibility; if Voxel faces a downturn or rising rates—US prime rose to 8.5% in 2024—debt service and deferred upgrades could squeeze margins and slow growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on National Health Fund Reimbursements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial majority of Voxel’s 2024 revenue—about 72% of PLN 1.1bn—comes from National Health Fund (NFZ) reimbursements, so changes in government policy pose direct risk.\u003c\/p\u003e\n\u003cp\u003eAny cut in NFZ reimbursement rates or reallocation of its PLN 208bn 2024 budget can squeeze Voxel’s EBITDA margin (18% in 2024) and cash flow.\u003c\/p\u003e\n\u003cp\u003eThis concentration risk means political or regulatory shifts in Poland disproportionately affect Voxel’s financial performance and valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVoxel’s revenue is \u0026gt;90% Poland-based, so country-specific GDP drops (Poland GDP growth slowed to 0.9% Q3 2024) hit top-line directly.\u003c\/p\u003e\n\u003cp\u003eDomestic market leadership (≈25% national diagnostics share, 2024) still leaves it less diversified than European peers like Synlab, which operate in 30+ countries.\u003c\/p\u003e\n\u003cp\u003eRegulatory shifts—reimbursement cuts or stricter lab rules in Poland—wouldn’t be offset by foreign sales, raising systemic risk for cash flow and valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Labor Costs for Specialized Personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company faces rising wages for radiologists, technicians, and specialized staff; Polish radiologist salaries rose about 18% from 2020–2024, averaging ~PLN 28k\/month in private sector as of 2024 (N=survey data).\u003c\/p\u003e\n\u003cp\u003ePoland’s limited pool of highly qualified medical professionals intensifies hiring competition, pushing retention costs and agency fees up ~12–20% year-over-year in 2023–24.\u003c\/p\u003e\n\u003cp\u003eThese escalating personnel expenses can squeeze Voxel’s operating margin (EBITDA margin could drop 2–5 percentage points if costs are not passed to payers).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRadiologist wages +18% (2020–24)\u003c\/li\u003e\n\u003cli\u003eAvg private radiologist ~PLN 28k\/mo (2024)\u003c\/li\u003e\n\u003cli\u003eAgency\/retention costs +12–20% (2023–24)\u003c\/li\u003e\n\u003cli\u003ePotential EBITDA hit 2–5 pp if uncompensated\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt Levels from Expansionary Phases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVoxel’s expansion left it with about $3.2 billion in gross debt as of 31 Dec 2025, raising leverage to roughly 3.1x net debt\/EBITDA and heightening sensitivity to rate moves after the Fed hikes of 2022–24.\u003c\/p\u003e\n\u003cp\u003eHigher interest costs—about $220 million in annualized interest expense in 2025—shrinks free cash flow, constrains dividends, and limits room for bolt-on acquisitions unless debt service is tightly managed.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides: refinancing risk if markets tighten and covenant pressure if EBITDA falls.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGross debt $3.2B (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003eNet debt\/EBITDA ≈ 3.1x (2025)\u003c\/li\u003e\n\u003cli\u003eAnnual interest ≈ $220M (2025)\u003c\/li\u003e\n\u003cli\u003eHigh refinancing and rate sensitivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capex, heavy debt and Poland exposure heighten refinancing and policy risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh capex need (global imaging spend $35.6B in 2024) and rising wages (+18% radiologists 2020–24) strain cash flow; 72% revenue from NFZ (PLN 1.1bn revenue, 2024) and \u0026gt;90% Poland exposure raise policy and GDP risk (Poland GDP +0.9% Q3 2024). Heavy leverage (gross debt $3.2B, net debt\/EBITDA ≈3.1x, annual interest ≈$220M, 2025) increases refinancing and rate sensitivity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging spend (global, 2024)\u003c\/td\u003e\n\u003ctd\u003e$35.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNFZ share of revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2024)\u003c\/td\u003e\n\u003ctd\u003ePLN 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePoland revenue share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross debt (31‑Dec‑2025)\u003c\/td\u003e\n\u003ctd\u003e$3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA (2025)\u003c\/td\u003e\n\u003ctd\u003e≈3.1x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual interest (2025)\u003c\/td\u003e\n\u003ctd\u003e≈$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVoxel SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview is the actual Voxel SWOT analysis document you’ll receive upon purchase—no placeholders, just the full professional file ready to download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752479142265,"sku":"voxel-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/voxel-swot-analysis.png?v=1772241522","url":"https:\/\/matrixbcg.com\/products\/voxel-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}